A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
Trial details
- Registry ID
- NCT03427125
- Phase
- Phase 3
The FDA approved Sevelamer Carbonate (Renvela) on 19 Oct 2007.
Drug identity checked against registry records
Also recorded as Renvela
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on DialysisNCT03427125 | Ardelyx | Phase 3 | Completed | 2019-11-15Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2007-10-19Day | Sevelamer Carbonate | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA022127", "applicant_as_listed_by_fda": "SANOFI", "brand_names": ["RENVELA"], "active_ingredients": ["SEVELAMER CARBONATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20071019", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |